Trials / Recruiting
RecruitingNCT06981754
Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery
Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 588 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone palmitate | Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision. |
| DRUG | Dexamethasone | Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision. |
Timeline
- Start date
- 2025-06-17
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
- First posted
- 2025-05-21
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06981754. Inclusion in this directory is not an endorsement.